BioTech Medics Announces Projection OF $1 Million in First Quarter Wholesale SHBAN Orders

DALLAS, TX -- BioTech Medics, Inc. (PINKSHEETS: BTMD) announced today from discussions with BioTech’s EU distributor MCM in the UK that MCM’s negotiations with various established EU and Asian distributors has resulted in indications of SHBAN wholesale purchase orders aggregating near $1 million (US$) for the first quarter of 2007. MCM is in the process of sorting EU and UK documentation requirements with the various regulatory agencies to facilitate the orders.

"SHBAN™ is currently manufactured in the USA by BioTech in a 3 oz. Go Anywhere Hand Sanitizer Spray Bottle. SHBAN has been clinically proven to kill the Avian Bird Flu virus and other viruses upon contact without harming humans, animals and the environment. The clear superiority of SHBAN over other hand disinfectants is that SHBAN is longer lasting. SHBAN does not evaporate within one minute after application (compared to alcohol based hand sanitizers). SHBAN leaves a clear invisible film on the hands to maximize protection. SHBAN is non-toxic (when used as directed), it is non-bleaching and has no toxic odors. Additionally, the SHBAN 3oz. size is convenient to carry in a purse, briefcase, backpack, waist pouch or vehicle.


Highlighted Links
http://www.biotechmedics.com

http://www.shban.com


SHBAN is protected under US Letters of Patent #5,514.808, #5,574,050, #5,679,711 5,679 and #5,585,391. BioTech Medics will provide SHBAN samples to government or world health officials should they desire to independently test the SHBAN topical solution with their Avian Bird Flu Virus issues.

BioTech Medics is a 21st Century Alternative Medicine corporation. BioTech has Pain Management & Wellness Centers which feature the NeuroLase Therapeutic Medical Laser, FDA cleared to reduce or eliminate muscular, skeletal or arthritic pain without drugs or surgery.

Safe Harbor for Forward-Looking Statements.

This press contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the “Act”). Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. The FDA has made no evaluation of SHBAN. SHBAN is not made to cure or treat any disease.